Form 4: Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Reports Stock Transactions

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, executed stock transactions on August 1, 2024, involving the exercise of stock options and subsequent sale of shares.

Summary

• On August 1, 2024, Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences, exercised stock options to acquire 2,996 shares of common stock at a price of $79.02 per share.
• Following the exercise of these options, Lippoldt sold 2,996 shares at a weighted average price of $154.013 per share, with individual sales prices ranging from $150.07 to $154.50.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 24, 2023.
• After these transactions, Lippoldt directly owns 39,740 shares of common stock and holds options for 43,372 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports routine stock transactions by an executive under a pre-existing trading plan. There is no indication of positive or negative news for the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the existence of a 10b5-1 plan mitigates this concern.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are usually not significant unless they represent a large proportion of the executive's holdings or are timed suspiciously close to major company announcements.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard practice for executives to manage their stock transactions and avoid accusations of insider trading.
• The reported transactions are typical for executives at publicly traded companies like Neurocrine Biosciences; similar transactions are regularly reported by executives at companies such as Amgen, Biogen, and Gilead Sciences.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders, as they are part of a pre-arranged trading plan.

Key Dates